Global Antibacterial (Drug) Resistance Market Insights and Forecast to 2026
- BMR3911189
- 182 Pages
- June 2020
- Healthcare
Market Analysis and Insights: Global Antibacterial (Drug) Resistance Market
Prior to COVID-19, the market for Antibacterial (Drug) Resistance was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Antibacterial (Drug) Resistance is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Antibacterial (Drug) Resistance market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Antibacterial (Drug) Resistance market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Antibacterial (Drug) Resistance industry.
Global Antibacterial (Drug) Resistance Scope and Segment
Antibacterial (Drug) Resistance market is segmented by Type, and by Indication. Players, stakeholders, and other participants in the global Antibacterial (Drug) Resistance market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Indication for the period 2015-2026.
The following manufacturers are covered in this report:
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Antibacterial (Drug) Resistance Breakdown Data by Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Antibacterial (Drug) Resistance Breakdown Data by Indication
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Regional and Country-level Analysis
The Antibacterial (Drug) Resistance market is analysed and market size information is provided by regions (countries).
The key regions covered in the Antibacterial (Drug) Resistance market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Indication segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Antibacterial (Drug) Resistance Market Share Analysis
1.1 Antibacterial (Drug) Resistance Product Introduction
1.2 Market Segments
1.3 Key Antibacterial (Drug) Resistance Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type
1.4.2 Telavancin (Vibativ)
1.4.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
1.4.4 Fidaxomicin (Dificid / Dificlir)
1.4.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
1.4.6 Dalbavancin (Dalvance/ Xydalba)
1.4.7 Tedizolid Phosphate (Sivextro)
1.4.8 Oritavancin (Orbactiv/ Nuvocid)
1.4.9 Ceftolozane-Tazobactam (Zerbaxa)
1.4.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
1.4.11 PHASE III DRUGS
1.5 Market by Indication
1.5.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication
1.5.2 Complicated Urinary Tract Infection (CUTI)
1.5.3 Complicated Intra-Abdominal Infections (CIAI)
1.5.4 Blood Stream Infections (BSI)
1.5.5 Clostridium Difficile Infections (CDI)
1.5.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
1.5.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.5.8 Community Acquired Bacterial Pneumonia (CABP)
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Antibacterial (Drug) Resistance Market Size, Estimates and Forecasts
2.1.1 Global Antibacterial (Drug) Resistance Revenue 2015-2026
2.1.2 Global Antibacterial (Drug) Resistance Sales 2015-2026
2.2 Global Antibacterial (Drug) Resistance, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Antibacterial (Drug) Resistance Competitor Landscape by Players
3.1 Antibacterial (Drug) Resistance Sales by Manufacturers
3.1.1 Antibacterial (Drug) Resistance Sales by Manufacturers (2015-2020)
3.1.2 Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2015-2020)
3.2 Antibacterial (Drug) Resistance Revenue by Manufacturers
3.2.1 Antibacterial (Drug) Resistance Revenue by Manufacturers (2015-2020)
3.2.2 Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Antibacterial (Drug) Resistance Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Antibacterial (Drug) Resistance Revenue in 2019
3.2.5 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Antibacterial (Drug) Resistance Price by Manufacturers
3.4 Antibacterial (Drug) Resistance Manufacturing Base Distribution, Product Types
3.4.1 Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Antibacterial (Drug) Resistance Product Type
3.4.3 Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Antibacterial (Drug) Resistance Market Size by Type (2015-2020)
4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2015-2020)
4.1.2 Global Antibacterial (Drug) Resistance Revenue by Type (2015-2020)
4.1.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Antibacterial (Drug) Resistance Market Size Forecast by Type (2021-2026)
4.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type (2021-2026)
4.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type (2021-2026)
4.2.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Antibacterial (Drug) Resistance Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Indication (2015-2026)
5.1 Global Antibacterial (Drug) Resistance Market Size by Indication (2015-2020)
5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2015-2020)
5.1.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2015-2020)
5.1.3 Antibacterial (Drug) Resistance Price by Indication (2015-2020)
5.2 Antibacterial (Drug) Resistance Market Size Forecast by Indication (2021-2026)
5.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2021-2026)
5.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2021-2026)
5.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Indication (2021-2026)
6 North America
6.1 North America Antibacterial (Drug) Resistance by Country
6.1.1 North America Antibacterial (Drug) Resistance Sales by Country
6.1.2 North America Antibacterial (Drug) Resistance Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Antibacterial (Drug) Resistance Market Facts & Figures by Type
6.3 North America Antibacterial (Drug) Resistance Market Facts & Figures by Indication
7 Europe
7.1 Europe Antibacterial (Drug) Resistance by Country
7.1.1 Europe Antibacterial (Drug) Resistance Sales by Country
7.1.2 Europe Antibacterial (Drug) Resistance Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Type
7.3 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Indication
8 Asia Pacific
8.1 Asia Pacific Antibacterial (Drug) Resistance by Region
8.1.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Region
8.1.2 Asia Pacific Antibacterial (Drug) Resistance Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Type
8.3 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Indication
9 Latin America
9.1 Latin America Antibacterial (Drug) Resistance by Country
9.1.1 Latin America Antibacterial (Drug) Resistance Sales by Country
9.1.2 Latin America Antibacterial (Drug) Resistance Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Antibacterial (Drug) Resistance Market Facts & Figures by Type
9.3 Central & South America Antibacterial (Drug) Resistance Market Facts & Figures by Indication
10 Middle East and Africa
10.1 Middle East and Africa Antibacterial (Drug) Resistance by Country
10.1.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
10.1.2 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Type
10.3 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Indication
11 Company Profiles
11.1 Melinta Therapeutics
11.1.1 Melinta Therapeutics Corporation Information
11.1.2 Melinta Therapeutics Description and Business Overview
11.1.3 Melinta Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
11.1.5 Melinta Therapeutics Related Developments
11.2 Allergan
11.2.1 Allergan Corporation Information
11.2.2 Allergan Description and Business Overview
11.2.3 Allergan Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Allergan Antibacterial (Drug) Resistance Products Offered
11.2.5 Allergan Related Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Description and Business Overview
11.3.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck Antibacterial (Drug) Resistance Products Offered
11.3.5 Merck Related Developments
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Corporation Information
11.4.2 Abbott Laboratories Description and Business Overview
11.4.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Products Offered
11.4.5 Abbott Laboratories Related Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Description and Business Overview
11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Antibacterial (Drug) Resistance Products Offered
11.5.5 Pfizer Related Developments
11.6 GSK
11.6.1 GSK Corporation Information
11.6.2 GSK Description and Business Overview
11.6.3 GSK Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GSK Antibacterial (Drug) Resistance Products Offered
11.6.5 GSK Related Developments
11.7 PENDOPHARM
11.7.1 PENDOPHARM Corporation Information
11.7.2 PENDOPHARM Description and Business Overview
11.7.3 PENDOPHARM Sales, Revenue and Gross Margin (2015-2020)
11.7.4 PENDOPHARM Antibacterial (Drug) Resistance Products Offered
11.7.5 PENDOPHARM Related Developments
11.8 Absynth Biologics
11.8.1 Absynth Biologics Corporation Information
11.8.2 Absynth Biologics Description and Business Overview
11.8.3 Absynth Biologics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Absynth Biologics Antibacterial (Drug) Resistance Products Offered
11.8.5 Absynth Biologics Related Developments
11.9 Achaogen
11.9.1 Achaogen Corporation Information
11.9.2 Achaogen Description and Business Overview
11.9.3 Achaogen Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Achaogen Antibacterial (Drug) Resistance Products Offered
11.9.5 Achaogen Related Developments
11.10 Acino Holdings
11.10.1 Acino Holdings Corporation Information
11.10.2 Acino Holdings Description and Business Overview
11.10.3 Acino Holdings Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Acino Holdings Antibacterial (Drug) Resistance Products Offered
11.10.5 Acino Holdings Related Developments
11.1 Melinta Therapeutics
11.1.1 Melinta Therapeutics Corporation Information
11.1.2 Melinta Therapeutics Description and Business Overview
11.1.3 Melinta Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered
11.1.5 Melinta Therapeutics Related Developments
11.12 Austell Laboratories
11.12.1 Austell Laboratories Corporation Information
11.12.2 Austell Laboratories Description and Business Overview
11.12.3 Austell Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Austell Laboratories Products Offered
11.12.5 Austell Laboratories Related Developments
11.13 Assembly Biosciences
11.13.1 Assembly Biosciences Corporation Information
11.13.2 Assembly Biosciences Description and Business Overview
11.13.3 Assembly Biosciences Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Assembly Biosciences Products Offered
11.13.5 Assembly Biosciences Related Developments
11.14 Arpida
11.14.1 Arpida Corporation Information
11.14.2 Arpida Description and Business Overview
11.14.3 Arpida Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Arpida Products Offered
11.14.5 Arpida Related Developments
11.15 Demuris
11.15.1 Demuris Corporation Information
11.15.2 Demuris Description and Business Overview
11.15.3 Demuris Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Demuris Products Offered
11.15.5 Demuris Related Developments
11.16 Evolva Holding
11.16.1 Evolva Holding Corporation Information
11.16.2 Evolva Holding Description and Business Overview
11.16.3 Evolva Holding Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Evolva Holding Products Offered
11.16.5 Evolva Holding Related Developments
11.17 ContraFect
11.17.1 ContraFect Corporation Information
11.17.2 ContraFect Description and Business Overview
11.17.3 ContraFect Sales, Revenue and Gross Margin (2015-2020)
11.17.4 ContraFect Products Offered
11.17.5 ContraFect Related Developments
11.18 Cerexa
11.18.1 Cerexa Corporation Information
11.18.2 Cerexa Description and Business Overview
11.18.3 Cerexa Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Cerexa Products Offered
11.18.5 Cerexa Related Developments
11.19 InterMune
11.19.1 InterMune Corporation Information
11.19.2 InterMune Description and Business Overview
11.19.3 InterMune Sales, Revenue and Gross Margin (2015-2020)
11.19.4 InterMune Products Offered
11.19.5 InterMune Related Developments
11.20 Isis Pharmaceuticals
11.20.1 Isis Pharmaceuticals Corporation Information
11.20.2 Isis Pharmaceuticals Description and Business Overview
11.20.3 Isis Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Isis Pharmaceuticals Products Offered
11.20.5 Isis Pharmaceuticals Related Developments
11.21 Lyndra
11.21.1 Lyndra Corporation Information
11.21.2 Lyndra Description and Business Overview
11.21.3 Lyndra Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Lyndra Products Offered
11.21.5 Lyndra Related Developments
11.22 Microbecide
11.22.1 Microbecide Corporation Information
11.22.2 Microbecide Description and Business Overview
11.22.3 Microbecide Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Microbecide Products Offered
11.22.5 Microbecide Related Developments
11.23 Morphochem
11.23.1 Morphochem Corporation Information
11.23.2 Morphochem Description and Business Overview
11.23.3 Morphochem Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Morphochem Products Offered
11.23.5 Morphochem Related Developments
11.24 Nabriva Therapeutics
11.24.1 Nabriva Therapeutics Corporation Information
11.24.2 Nabriva Therapeutics Description and Business Overview
11.24.3 Nabriva Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.24.4 Nabriva Therapeutics Products Offered
11.24.5 Nabriva Therapeutics Related Developments
11.25 NanoSafe Coatings
11.25.1 NanoSafe Coatings Corporation Information
11.25.2 NanoSafe Coatings Description and Business Overview
11.25.3 NanoSafe Coatings Sales, Revenue and Gross Margin (2015-2020)
11.25.4 NanoSafe Coatings Products Offered
11.25.5 NanoSafe Coatings Related Developments
11.26 Novexel
11.26.1 Novexel Corporation Information
11.26.2 Novexel Description and Business Overview
11.26.3 Novexel Sales, Revenue and Gross Margin (2015-2020)
11.26.4 Novexel Products Offered
11.26.5 Novexel Related Developments
11.27 Osel
11.27.1 Osel Corporation Information
11.27.2 Osel Description and Business Overview
11.27.3 Osel Sales, Revenue and Gross Margin (2015-2020)
11.27.4 Osel Products Offered
11.27.5 Osel Related Developments
11.28 VenatoRx Pharmaceuticals
11.28.1 VenatoRx Pharmaceuticals Corporation Information
11.28.2 VenatoRx Pharmaceuticals Description and Business Overview
11.28.3 VenatoRx Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.28.4 VenatoRx Pharmaceuticals Products Offered
11.28.5 VenatoRx Pharmaceuticals Related Developments
11.29 AAIPharma Services
11.29.1 AAIPharma Services Corporation Information
11.29.2 AAIPharma Services Description and Business Overview
11.29.3 AAIPharma Services Sales, Revenue and Gross Margin (2015-2020)
11.29.4 AAIPharma Services Products Offered
11.29.5 AAIPharma Services Related Developments
11.30 ANTABIO
11.30.1 ANTABIO Corporation Information
11.30.2 ANTABIO Description and Business Overview
11.30.3 ANTABIO Sales, Revenue and Gross Margin (2015-2020)
11.30.4 ANTABIO Products Offered
11.30.5 ANTABIO Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Antibacterial (Drug) Resistance Market Estimates and Projections by Region
12.1.1 Global Antibacterial (Drug) Resistance Sales Forecast by Regions 2021-2026
12.1.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Regions 2021-2026
12.2 North America Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
12.2.1 North America: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
12.2.2 North America: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
12.2.3 North America: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
12.3 Europe Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
12.3.1 Europe: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
12.3.2 Europe: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
12.3.3 Europe: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Antibacterial (Drug) Resistance Market Size Forecast by Region (2021-2026)
12.5 Latin America Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
12.5.1 Latin America: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
12.5.2 Latin America: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
12.5.3 Latin America: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Antibacterial (Drug) Resistance Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Antibacterial (Drug) Resistance Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Antibacterial (Drug) Resistance Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Antibacterial (Drug) Resistance Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Antibacterial (Drug) Resistance Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Antibacterial (Drug) Resistance Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Antibacterial (Drug) Resistance Market Segments
Table 2. Ranking of Global Top Antibacterial (Drug) Resistance Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Telavancin (Vibativ)
Table 5. Major Manufacturers of Ceftaroline Fosamil (Teflaro/ Zinforo)
Table 6. Major Manufacturers of Fidaxomicin (Dificid / Dificlir)
Table 7. Major Manufacturers of Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Table 8. Major Manufacturers of Dalbavancin (Dalvance/ Xydalba)
Table 9. Major Manufacturers of Tedizolid Phosphate (Sivextro)
Table 10. Major Manufacturers of Oritavancin (Orbactiv/ Nuvocid)
Table 11. Major Manufacturers of Ceftolozane-Tazobactam (Zerbaxa)
Table 12. Major Manufacturers of Ceftazidime-Avibactam (Avycaz/ Zavicefta)
Table 13. Major Manufacturers of PHASE III DRUGS
Table 14. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication 2020-2026 (K Units)
Table 15. Global Antibacterial (Drug) Resistance Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Antibacterial (Drug) Resistance Sales by Regions 2015-2020 (K Units)
Table 17. Global Antibacterial (Drug) Resistance Sales Market Share by Regions (2015-2020)
Table 18. Global Antibacterial (Drug) Resistance Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Antibacterial (Drug) Resistance Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Antibacterial (Drug) Resistance Sales Share by Manufacturers (2015-2020)
Table 21. Global Antibacterial (Drug) Resistance Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibacterial (Drug) Resistance as of 2019)
Table 23. Antibacterial (Drug) Resistance Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Antibacterial (Drug) Resistance Price (2015-2020) (USD/Unit)
Table 26. Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Antibacterial (Drug) Resistance Product Type
Table 28. Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Antibacterial (Drug) Resistance Sales by Type (2015-2020) (K Units)
Table 31. Global Antibacterial (Drug) Resistance Sales Share by Type (2015-2020)
Table 32. Global Antibacterial (Drug) Resistance Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Antibacterial (Drug) Resistance Revenue Share by Type (2015-2020)
Table 34. Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Antibacterial (Drug) Resistance Sales by Indication (2015-2020) (K Units)
Table 36. Global Antibacterial (Drug) Resistance Sales Share by Indication (2015-2020)
Table 37. North America Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 38. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 39. North America Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 41. North America Antibacterial (Drug) Resistance Sales by Type (2015-2020) (K Units)
Table 42. North America Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 43. North America Antibacterial (Drug) Resistance Sales by Indication (2015-2020) (K Units)
Table 44. North America Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Table 45. Europe Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 46. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 47. Europe Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 49. Europe Antibacterial (Drug) Resistance Sales by Type (2015-2020) (K Units)
Table 50. Europe Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 51. Europe Antibacterial (Drug) Resistance Sales by Indication (2015-2020) (K Units)
Table 52. Europe Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Table 53. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Antibacterial (Drug) Resistance Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Antibacterial (Drug) Resistance Sales by Indication (2015-2020) (K Units)
Table 60. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Table 61. Latin America Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 62. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 65. Latin America Antibacterial (Drug) Resistance Sales by Type (2015-2020) (K Units)
Table 66. Latin America Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 67. Latin America Antibacterial (Drug) Resistance Sales by Indication (2015-2020) (K Units)
Table 68. Latin America Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Table 69. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Antibacterial (Drug) Resistance Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Antibacterial (Drug) Resistance Sales by Indication (2015-2020) (K Units)
Table 76. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Table 77. Melinta Therapeutics Corporation Information
Table 78. Melinta Therapeutics Description and Major Businesses
Table 79. Melinta Therapeutics Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Melinta Therapeutics Product
Table 81. Melinta Therapeutics Recent Development
Table 82. Allergan Corporation Information
Table 83. Allergan Description and Major Businesses
Table 84. Allergan Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Allergan Product
Table 86. Allergan Recent Development
Table 87. Merck Corporation Information
Table 88. Merck Description and Major Businesses
Table 89. Merck Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Merck Product
Table 91. Merck Recent Development
Table 92. Abbott Laboratories Corporation Information
Table 93. Abbott Laboratories Description and Major Businesses
Table 94. Abbott Laboratories Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Abbott Laboratories Product
Table 96. Abbott Laboratories Recent Development
Table 97. Pfizer Corporation Information
Table 98. Pfizer Description and Major Businesses
Table 99. Pfizer Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Pfizer Product
Table 101. Pfizer Recent Development
Table 102. GSK Corporation Information
Table 103. GSK Description and Major Businesses
Table 104. GSK Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. GSK Product
Table 106. GSK Recent Development
Table 107. PENDOPHARM Corporation Information
Table 108. PENDOPHARM Description and Major Businesses
Table 109. PENDOPHARM Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. PENDOPHARM Product
Table 111. PENDOPHARM Recent Development
Table 112. Absynth Biologics Corporation Information
Table 113. Absynth Biologics Description and Major Businesses
Table 114. Absynth Biologics Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Absynth Biologics Product
Table 116. Absynth Biologics Recent Development
Table 117. Achaogen Corporation Information
Table 118. Achaogen Description and Major Businesses
Table 119. Achaogen Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Achaogen Product
Table 121. Achaogen Recent Development
Table 122. Acino Holdings Corporation Information
Table 123. Acino Holdings Description and Major Businesses
Table 124. Acino Holdings Antibacterial (Drug) Resistance Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Acino Holdings Product
Table 126. Acino Holdings Recent Development
Table 127. Aventis Pharma Corporation Information
Table 128. Aventis Pharma Description and Major Businesses
Table 129. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 130. Aventis Pharma Product
Table 131. Aventis Pharma Recent Development
Table 132. Austell Laboratories Corporation Information
Table 133. Austell Laboratories Description and Major Businesses
Table 134. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 135. Austell Laboratories Product
Table 136. Austell Laboratories Recent Development
Table 137. Assembly Biosciences Corporation Information
Table 138. Assembly Biosciences Description and Major Businesses
Table 139. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 140. Assembly Biosciences Product
Table 141. Assembly Biosciences Recent Development
Table 142. Arpida Corporation Information
Table 143. Arpida Description and Major Businesses
Table 144. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 145. Arpida Product
Table 146. Arpida Recent Development
Table 147. Demuris Corporation Information
Table 148. Demuris Description and Major Businesses
Table 149. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 150. Demuris Product
Table 151. Demuris Recent Development
Table 152. Evolva Holding Corporation Information
Table 153. Evolva Holding Description and Major Businesses
Table 154. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 155. Evolva Holding Product
Table 156. Evolva Holding Recent Development
Table 157. ContraFect Corporation Information
Table 158. ContraFect Description and Major Businesses
Table 159. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 160. ContraFect Product
Table 161. ContraFect Recent Development
Table 162. Cerexa Corporation Information
Table 163. Cerexa Description and Major Businesses
Table 164. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 165. Cerexa Product
Table 166. Cerexa Recent Development
Table 167. InterMune Corporation Information
Table 168. InterMune Description and Major Businesses
Table 169. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 170. InterMune Product
Table 171. InterMune Recent Development
Table 172. Isis Pharmaceuticals Corporation Information
Table 173. Isis Pharmaceuticals Description and Major Businesses
Table 174. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 175. Isis Pharmaceuticals Product
Table 176. Isis Pharmaceuticals Recent Development
Table 177. Lyndra Corporation Information
Table 178. Lyndra Description and Major Businesses
Table 179. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 180. Lyndra Product
Table 181. Lyndra Recent Development
Table 182. Microbecide Corporation Information
Table 183. Microbecide Description and Major Businesses
Table 184. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 185. Microbecide Product
Table 186. Microbecide Recent Development
Table 187. Morphochem Corporation Information
Table 188. Morphochem Description and Major Businesses
Table 189. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 190. Morphochem Product
Table 191. Morphochem Recent Development
Table 192. Nabriva Therapeutics Corporation Information
Table 193. Nabriva Therapeutics Description and Major Businesses
Table 194. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 195. Nabriva Therapeutics Product
Table 196. Nabriva Therapeutics Recent Development
Table 197. NanoSafe Coatings Corporation Information
Table 198. NanoSafe Coatings Description and Major Businesses
Table 199. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 200. NanoSafe Coatings Product
Table 201. NanoSafe Coatings Recent Development
Table 202. Novexel Corporation Information
Table 203. Novexel Description and Major Businesses
Table 204. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 205. Novexel Product
Table 206. Novexel Recent Development
Table 207. Osel Corporation Information
Table 208. Osel Description and Major Businesses
Table 209. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 210. Osel Product
Table 211. Osel Recent Development
Table 212. VenatoRx Pharmaceuticals Corporation Information
Table 213. VenatoRx Pharmaceuticals Description and Major Businesses
Table 214. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 215. VenatoRx Pharmaceuticals Product
Table 216. VenatoRx Pharmaceuticals Recent Development
Table 217. AAIPharma Services Corporation Information
Table 218. AAIPharma Services Description and Major Businesses
Table 219. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 220. AAIPharma Services Product
Table 221. AAIPharma Services Recent Development
Table 222. ANTABIO Corporation Information
Table 223. ANTABIO Description and Major Businesses
Table 224. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 225. ANTABIO Product
Table 226. ANTABIO Recent Development
Table 227. Global Antibacterial (Drug) Resistance Sales Forecast by Regions (2021-2026) (K Units)
Table 228. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Regions (2021-2026)
Table 229. Global Antibacterial (Drug) Resistance Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 230. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Regions (2021-2026)
Table 231. North America: Antibacterial (Drug) Resistance Sales Forecast by Country (2021-2026) (K Units)
Table 232. North America: Antibacterial (Drug) Resistance Revenue Forecast by Country (2021-2026) (US$ Million)
Table 233. Europe: Antibacterial (Drug) Resistance Sales Forecast by Country (2021-2026) (K Units)
Table 234. Europe: Antibacterial (Drug) Resistance Revenue Forecast by Country (2021-2026) (US$ Million)
Table 235. Asia Pacific: Antibacterial (Drug) Resistance Sales Forecast by Region (2021-2026) (K Units)
Table 236. Asia Pacific: Antibacterial (Drug) Resistance Revenue Forecast by Region (2021-2026) (US$ Million)
Table 237. Latin America: Antibacterial (Drug) Resistance Sales Forecast by Country (2021-2026) (K Units)
Table 238. Latin America: Antibacterial (Drug) Resistance Revenue Forecast by Country (2021-2026) (US$ Million)
Table 239. Middle East and Africa: Antibacterial (Drug) Resistance Sales Forecast by Country (2021-2026) (K Units)
Table 240. Middle East and Africa: Antibacterial (Drug) Resistance Revenue Forecast by Country (2021-2026) (US$ Million)
Table 241. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 242. Key Challenges
Table 243. Market Risks
Table 244. Main Points Interviewed from Key Antibacterial (Drug) Resistance Players
Table 245. Antibacterial (Drug) Resistance Customers List
Table 246. Antibacterial (Drug) Resistance Distributors List
Table 247. Research Programs/Design for This Report
Table 248. Key Data Information from Secondary Sources
Table 249. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibacterial (Drug) Resistance Product Picture
Figure 2. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2020 & 2026
Figure 3. Telavancin (Vibativ) Product Picture
Figure 4. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Picture
Figure 5. Fidaxomicin (Dificid / Dificlir) Product Picture
Figure 6. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Picture
Figure 7. Dalbavancin (Dalvance/ Xydalba) Product Picture
Figure 8. Tedizolid Phosphate (Sivextro) Product Picture
Figure 9. Oritavancin (Orbactiv/ Nuvocid) Product Picture
Figure 10. Ceftolozane-Tazobactam (Zerbaxa) Product Picture
Figure 11. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Product Picture
Figure 12. PHASE III DRUGS Product Picture
Figure 13. Global Antibacterial (Drug) Resistance Sales Market Share by Indication in 2020 & 2026
Figure 14. Complicated Urinary Tract Infection (CUTI)
Figure 15. Complicated Intra-Abdominal Infections (CIAI)
Figure 16. Blood Stream Infections (BSI)
Figure 17. Clostridium Difficile Infections (CDI)
Figure 18. Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Figure 19. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Figure 20. Community Acquired Bacterial Pneumonia (CABP)
Figure 21. Antibacterial (Drug) Resistance Report Years Considered
Figure 22. Global Antibacterial (Drug) Resistance Market Size 2015-2026 (US$ Million)
Figure 23. Global Antibacterial (Drug) Resistance Sales 2015-2026 (K Units)
Figure 24. Global Antibacterial (Drug) Resistance Market Size Market Share by Region: 2020 Versus 2026
Figure 25. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2015-2020)
Figure 26. Global Antibacterial (Drug) Resistance Sales Market Share by Region in 2019
Figure 27. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2015-2020)
Figure 28. Global Antibacterial (Drug) Resistance Revenue Market Share by Region in 2019
Figure 29. Global Antibacterial (Drug) Resistance Sales Share by Manufacturer in 2019
Figure 30. The Top 10 and 5 Players Market Share by Antibacterial (Drug) Resistance Revenue in 2019
Figure 31. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 32. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2015-2020)
Figure 33. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2019
Figure 34. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2015-2020)
Figure 35. Global Antibacterial (Drug) Resistance Revenue Market Share by Type in 2019
Figure 36. Global Antibacterial (Drug) Resistance Market Share by Price Range (2015-2020)
Figure 37. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2015-2020)
Figure 38. Global Antibacterial (Drug) Resistance Sales Market Share by Indication in 2019
Figure 39. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2015-2020)
Figure 40. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication in 2019
Figure 41. North America Antibacterial (Drug) Resistance Sales Growth Rate 2015-2020 (K Units)
Figure 42. North America Antibacterial (Drug) Resistance Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. North America Antibacterial (Drug) Resistance Sales Market Share by Country in 2019
Figure 44. North America Antibacterial (Drug) Resistance Revenue Market Share by Country in 2019
Figure 45. U.S. Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 46. U.S. Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Canada Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 48. Canada Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. North America Antibacterial (Drug) Resistance Market Share by Type in 2019
Figure 50. North America Antibacterial (Drug) Resistance Market Share by Indication in 2019
Figure 51. Europe Antibacterial (Drug) Resistance Sales Growth Rate 2015-2020 (K Units)
Figure 52. Europe Antibacterial (Drug) Resistance Revenue Growth Rate 2015-2020 (US$ Million)
Figure 53. Europe Antibacterial (Drug) Resistance Sales Market Share by Country in 2019
Figure 54. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country in 2019
Figure 55. Germany Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 56. Germany Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. France Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 58. France Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. U.K. Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 60. U.K. Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Italy Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 62. Italy Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Russia Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 64. Russia Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Europe Antibacterial (Drug) Resistance Market Share by Type in 2019
Figure 66. Europe Antibacterial (Drug) Resistance Market Share by Indication in 2019
Figure 67. Asia Pacific Antibacterial (Drug) Resistance Sales Growth Rate 2015-2020 (K Units)
Figure 68. Asia Pacific Antibacterial (Drug) Resistance Revenue Growth Rate 2015-2020 (US$ Million)
Figure 69. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region in 2019
Figure 70. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region in 2019
Figure 71. China Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 72. China Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Japan Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 74. Japan Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. South Korea Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 76. South Korea Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. India Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 78. India Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Australia Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 80. Australia Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Taiwan Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 82. Taiwan Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Indonesia Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 84. Indonesia Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Thailand Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 86. Thailand Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Malaysia Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 88. Malaysia Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Philippines Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 90. Philippines Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Vietnam Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 92. Vietnam Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Asia Pacific Antibacterial (Drug) Resistance Market Share by Type in 2019
Figure 94. Asia Pacific Antibacterial (Drug) Resistance Market Share by Indication in 2019
Figure 95. Latin America Antibacterial (Drug) Resistance Sales Growth Rate 2015-2020 (K Units)
Figure 96. Latin America Antibacterial (Drug) Resistance Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country in 2019
Figure 98. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country in 2019
Figure 99. Mexico Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 100. Mexico Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Brazil Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 102. Brazil Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Argentina Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 104. Argentina Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Latin America Antibacterial (Drug) Resistance Market Share by Type in 2019
Figure 106. Latin America Antibacterial (Drug) Resistance Market Share by Indication in 2019
Figure 107. Middle East and Africa Antibacterial (Drug) Resistance Sales Growth Rate 2015-2020 (K Units)
Figure 108. Middle East and Africa Antibacterial (Drug) Resistance Revenue Growth Rate 2015-2020 (US$ Million)
Figure 109. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country in 2019
Figure 110. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country in 2019
Figure 111. Turkey Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 112. Turkey Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 113. Saudi Arabia Antibacterial (Drug) Resistance Sales Growth Rate (2015-2020) (K Units)
Figure 114. Saudi Arabia Antibacterial (Drug) Resistance Revenue Growth Rate (2015-2020) (US$ Million)
Figure 115. U.A.E Ant
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
